Provided herein is a two-component photosensitizer, which demonstrated robust and selective killing effects for transfected HEK cells and affibody targeted A431 cancer cells when exposed to near infrared light excitation. Free MG2I is a pure and stable fluorogen; it is easy to synthesize and modify, and has no toxicity to cells. Unlike conventional photosensitizers, the dye and FAP itself has no photosensitizing effect until they are bound. Also unlike other activation methods, the activation step is achieved by adding the fluorogen, not the presence of the targeted molecule, requiring an active activation instead of a passive activation. This method offers the ability to locally switch-on and selective generation of singlet oxygen at the target site and can be used for a wide variety of molecular targets.

Provided herein is a two-component photosensitizer, which demonstrated robust and selective killing effects for transfected HEK cells and affibody targeted A431 cancer cells when exposed to near infrared light excitation. Free MG2I is a pure and stable fluorogen; it is easy to synthesize and modify, and has no toxicity to cells. Unlike conventional photosensitizers, the dye and FAP itself has no photosensitizing effect until they are bound. Also unlike other activation methods, the activation step is achieved by adding the fluorogen, not the presence of the targeted molecule, requiring an active activation instead of a passive activation. This method offers the ability to locally switch-on and selective generation of singlet oxygen at the target site and can be used for a wide variety of molecular targets.

This invention relates to a wax composition comprising a plurality of fatty acid amide compounds having the Formula (I):

##STR00001##

where R.sup.1, R.sup.2, n.sub.1, n.sub.2, m.sub.1, and m.sub.2 are as described herein. This invention also relates to a wax composition comprising: a) one or more fatty acid amide compounds having the Formula (II):

##STR00002##

and b) one or more fatty acid amide compounds having the Formula (III):

##STR00003##

where R.sup.1, R.sup.2, n.sub.1, and n.sub.2 are as described herein. This invention also relates to a fatty acid amide compound having the Formula (I) and a process for preparing a compound of Formula (I).

This invention relates to a wax composition comprising a plurality of fatty acid amide compounds having the Formula (I):

##STR00001##

where R.sup.1, R.sup.2, n.sub.1, n.sub.2, m.sub.1, and m.sub.2 are as described herein. This invention also relates to a wax composition comprising: a) one or more fatty acid amide compounds having the Formula (II):

##STR00002##

and b) one or more fatty acid amide compounds having the Formula (III):

##STR00003##

where R.sup.1, R.sup.2, n.sub.1, and n.sub.2 are as described herein. This invention also relates to a fatty acid amide compound having the Formula (I) and a process for preparing a compound of Formula (I).

Compounds are provided that function as thyromimetics, which compounds have utility for treating diseases such as neurodegenerative disorders. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation. Such compounds have the structure of Formula (I) as shown herein, or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof.

Compounds are provided that function as thyromimetics, which compounds have utility for treating diseases such as neurodegenerative disorders. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation. Such compounds have the structure of Formula (I) as shown herein, or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof.

This invention relates to a wax composition comprising a plurality of fatty acid amide compounds having the Formula (I): ##STR00001##
where R.sup.1, R.sup.2, n.sub.1, n.sub.2, m.sub.1, and m.sub.2 are as described herein. This invention also relates to a wax composition comprising: a) one or more fatty acid amide compounds having the Formula (II): ##STR00002##
and b) one or more fatty acid amide compounds having the Formula (III): ##STR00003##
where R.sup.1, R.sup.2, n.sub.1, and n.sub.2 are as described herein. This invention also relates to a fatty acid amide compound having the Formula (I) and a process for preparing a compound of Formula (I).

This invention relates to a wax composition comprising a plurality of fatty acid amide compounds having the Formula (I): ##STR00001##
where R.sup.1, R.sup.2, n.sub.1, n.sub.2, m.sub.1, and m.sub.2 are as described herein. This invention also relates to a wax composition comprising: a) one or more fatty acid amide compounds having the Formula (II): ##STR00002##
and b) one or more fatty acid amide compounds having the Formula (III): ##STR00003##
where R.sup.1, R.sup.2, n.sub.1, and n.sub.2 are as described herein. This invention also relates to a fatty acid amide compound having the Formula (I) and a process for preparing a compound of Formula (I).

A compound of formula (I), ##STR00001##
wherein R.sup.1 is an optionally substituted aryl or an optionally substituted heteroaryl, R.sup.2 is an optionally substituted aryl or an optionally substituted heteroaryl, and R.sup.3 is an optionally substituted alkylamino, an optionally substituted cycloalkylamino, an optionally substituted arylamino, an optionally substituted heterocyclylamino, an optionally substituted heterocyclyl, and an optionally substituted dialkylamino. A pharmaceutical composition which includes the compound of formula (I) and a pharmaceutically acceptable carrier and/or excipient. A method of treating colorectal cancer in a subject, whereby a therapeutically effective amount of the compound of formula (I) is administered to the subject.

A compound of formula (I), ##STR00001##
wherein R.sup.1 is an optionally substituted aryl or an optionally substituted heteroaryl, R.sup.2 is an optionally substituted aryl or an optionally substituted heteroaryl, and R.sup.3 is an optionally substituted alkylamino, an optionally substituted cycloalkylamino, an optionally substituted arylamino, an optionally substituted heterocyclylamino, an optionally substituted heterocyclyl, and an optionally substituted dialkylamino. A pharmaceutical composition which includes the compound of formula (I) and a pharmaceutically acceptable carrier and/or excipient. A method of treating colorectal cancer in a subject, whereby a therapeutically effective amount of the compound of formula (I) is administered to the subject.